Details

Autor(en) / Beteiligte

• Diacon, Andreas H
• Pym, Alexander
• Grobusch, Martin P
• de los Rios, Jorge M
• Gotuzzo, Eduardo
• Vasilyeva, Irina
• Leimane, Vaira
• Andries, Koen
• Bakare, Nyasha
• De Marez, Tine
• Haxaire-Theeuwes, Myriam
• Lounis, Nacer
• Meyvisch, Paul
• De Paepe, Els
• van Heeswijk, Rolf P.G
• Dannemann, Brian

Titel

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

Ist Teil von

• The New England journal of medicine, 2014-08, Vol.371 (8), p.723-732

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In this phase 2 study, the addition of bedaquiline to routine therapy for multidrug-resistant tuberculosis showed significant efficacy, with accelerated sputum-culture conversion and increased culture conversion at 24 and 120 weeks. The World Health Organization (WHO) estimates that the global incidence of tuberculosis in 2012 was 8.6 million cases, with 1.3 million deaths, predominantly occurring in developing countries. 1 Although there has been some progress in reducing tuberculosis cases and deaths in the past 20 years, multidrug-resistant tuberculosis (i.e., with resistance to at least isoniazid and rifampin) remains a major challenge. The 2012 global incidence of multidrug-resistant tuberculosis was 450,000 cases. 1 Therapy for multidrug-resistant tuberculosis is a long, arduous regimen of antiquated drugs that are mainly bacteriostatic and have an unfavorable side-effect profile. 2 The WHO reports that major efforts are needed to . . .